00:33 , Apr 6, 2018 |  BC Innovations  |  Targets & Mechanisms

GI Band-Aid

A trio of Science papers shows a leaky gut can drive systemic inflammation and autoimmunity by allowing bacteria and their products to escape the GI lumen and enter the bloodstream. The results open a variety...
00:51 , Feb 9, 2018 |  BC Innovations  |  Product R&D

Debugging the microbiome

BiomX Ltd. is moving phage therapies beyond infectious disease and into chronic conditions driven by the microbiome. The Israeli biotech has pieced together a suite of tools that can identify bad actors within microbial communities...
20:37 , Feb 2, 2018 |  BC Week In Review  |  Company News

BiomX licenses new microbiome targets

Microbiome company BiomX Ltd. (Ness Ziona, Israel) said it exclusively sublicensed a set of new bacterial targets from JSR Corp. (Tokyo:4185) to develop and commercialize bacteriophage-based therapies for inflammatory bowel disease (IBD). BiomX is using the...
13:00 , Jan 30, 2018 |  BC Extra  |  Company News

BiomX licenses new microbiome targets

Microbiome company BiomX Ltd. (Ness Ziona, Israel) said it exclusively sublicensed a set of new bacterial targets from JSR Corp. (Tokyo:4185) to develop and commercialize bacteriophage-based therapies for inflammatory bowel disease (IBD). BiomX is using...
15:04 , Dec 22, 2017 |  BC Week In Review  |  Company News

BiomX acquires microbiome company RondinX

BiomX Ltd. (Ness Ziona, Israel) acquired fellow microbiome company RondinX (Tel Aviv, Israel), including its computational discovery platform. BiomX said it also gains a pipeline of undisclosed microbial targets that are being validated to treat...
21:11 , Dec 19, 2017 |  BC Extra  |  Company News

BiomX acquires microbiome company RondinX

BiomX Ltd. (Ness Ziona, Israel) said it acquired fellow microbiome company RondinX (Tel Aviv, Israel), including its computational discovery platform. BiomX said it also gains a pipeline of undisclosed microbial targets that are being validated...
20:43 , May 19, 2017 |  BioCentury  |  Finance

BiomX’s balance

After identifying a handful of novel bacterial targets and bacteriophage candidates, BiomX Ltd. was able to attract $24 million in series A funding from some of industry's most active microbiome players. OrbiMed Advisors, the Johnson...